Arbutus Biopharma Corporation
ABUS
$2.80
$0.093.32%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -65.65% | -21.74% | -67.34% | -46.85% | 94.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -65.65% | -21.74% | -67.34% | -46.85% | 94.79% |
| Cost of Revenue | -23.47% | 0.57% | -22.88% | -1.01% | 19.45% |
| Gross Profit | 7.69% | -9.98% | -49.88% | -97.04% | -4.36% |
| SG&A Expenses | 20.05% | 67.25% | 15.00% | 13.49% | -7.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.67% | 10.46% | -15.88% | 2.03% | 14.23% |
| Operating Income | 2.07% | -21.35% | -36.83% | -59.10% | -1.70% |
| Income Before Tax | 11.95% | -14.44% | -20.45% | -44.32% | -2.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.95% | -14.44% | -20.45% | -3.64% | -2.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.95% | -14.44% | -20.45% | -3.64% | -2.87% |
| EBIT | 2.07% | -21.35% | -36.83% | -59.10% | -1.70% |
| EBITDA | 2.35% | -21.63% | -38.18% | -61.92% | -2.33% |
| EPS Basic | 18.72% | -3.18% | -7.86% | 4.80% | 14.08% |
| Normalized Basic EPS | 13.24% | -3.34% | -13.44% | -32.69% | 17.58% |
| EPS Diluted | 18.01% | -3.18% | -7.86% | 8.09% | 15.67% |
| Normalized Diluted EPS | 13.24% | -3.34% | -13.44% | -32.69% | 17.58% |
| Average Basic Shares Outstanding | 8.35% | 10.94% | 11.64% | 8.90% | 16.60% |
| Average Diluted Shares Outstanding | 8.35% | 10.94% | 11.64% | 8.90% | 16.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
